Georgiamune Pitch Deck: All 20 Slides + Teardown

The Homeostasis Narrative: Balancing Cancer and Autoimmunity

Georgiamune’s pitch deck begins not with a product, but with a biological philosophy. Slide 3, titled 'Loss of immune system homeostasis can lead to autoimmune diseases and cancer,' sets the stage for a platform-based investment. By visualizing the immune system as a scale, the company positions itself to capture two massive, distinct markets using the same underlying expertise in T-cell reprogramming. This slide is a masterclass in simplifying complex immunology for a generalist VC audience while maintaining scientific rigor.

Slide 1-4: The Vision and Platform

The deck opens with a clean, high-contrast design. Slide 2 defines the mission: 'Developing first-in-class immunotherapies.' Slide 4 introduces the 'novel biologic platforms,' which include both antibodies and small molecules. This is a critical strategic move; by not being wedded to a single modality, Georgiamune suggests their platform is versatile enough to address various targets with the most effective chemical or biological tool available.

Slide 5: The Pipeline Powerhouse

Slide 5 is arguably the most important slide for a Series A biotech company. It lists 11 distinct projects. The 'Clinical Programs' section highlights three lead assets: GIM-122 (Dual-Functioning Antibody for Cancer), GIM-531 (Treg Inhibitor for Cancer), and GIM-407 (Treg Activator for Autoimmune). All three are marked as 'First-in-Class' and are shown in the 'IND Enabling' stage. This indicates that the $75M raise is likely intended to push these three assets into Phase 1 clinical trials. The depth of the 'Drug Candidates' and 'Development Programs' further down the slide suggests a long-term 'company-building' play rather than a single-asset 'project-finance' play.

Slide 6-7: Institutional Credibility

In biotech, the team is the collateral. Slide 7, 'Innovative and Experienced Leadership,' is a 'who's who' of the pharmaceutical industry. The inclusion of Samir N. Khleif, MD (110+ patents), Sean Parker (Parker Institute), and Mace Rothenberg (Former CMO, Pfizer) provides an immediate stamp of approval. For an investor, this roster reduces execution risk—these are individuals who have successfully navigated the FDA and large-scale clinical trials before.

Slide 8-10: The Oncology Problem Statement

Slide 9 provides the 'Why Now?' factor. It acknowledges that Checkpoint Inhibitors (ICIs) are a $33B market but highlights a glaring weakness: they are ineffective for many patients, with a failure rate of >85% . Slide 10 positions GIM-122 as the solution to this resistance. By framing the product as a necessary evolution of a proven $33B market, Georgiamune makes the commercial upside feel tangible and urgent.

Slide 11: The Verily Partnership

Slide 11 highlights a strategic partnership with Verily (an Alphabet company). This is a significant 'moat' slide. It explains how Georgiamune uses Verily’s molecular and real-world evidence solutions to discover biomarkers and drive efficient clinical development. In an era where clinical trial costs are skyrocketing, showing a tech-enabled path to efficiency is a strong selling point for Series A investors.

Slide 12-20: Technical Deep Dive into Tregs

The final third of the deck focuses on the specific mechanism of action (MoA) regarding Regulatory T cells (Tregs). Slide 16 is particularly effective, contrasting Georgiamune’s 'selective' approach with 'current Treg depleting agents' that cause off-target effects. It argues that existing therapies (targeting CTLA4, CCR8, or CCR4) eliminate favorable effector T cells, whereas Georgiamune’s targets are 'highly selective to Tregs and not other cell types' (Slide 15). Slide 17 quantifies the oncology opportunity by US prevalence, citing 1.3M Melanoma cases and 730K Lung Cancer cases, grounding the science in market reality.

What Georgiamune Does Well

1. The Dual-Market Strategy: By using the same T-cell expertise to target both cancer (inhibition) and autoimmune disease (activation), Georgiamune creates a 'hedge' for investors. If one therapeutic area faces regulatory hurdles, the other provides a path forward.

2. Visualizing the 'Gap': Slide 9’s use of the >85% failure rate for ICIs is a powerful way to frame the problem. It doesn't attack the current standard of care; it identifies the massive population the standard of care leaves behind.

3. Heavyweight Endorsements: The board and advisor slides are not just names; they are strategic assets. Having a former FDA Deputy Commissioner (Amy Abernethy) on the board is a clear signal that the company is prepared for the regulatory gauntlet.

What is Missing from the Deck

1. The 'Ask' and Use of Funds: There is no slide detailing how much capital is being raised or how it will be allocated across the 11 pipeline programs. While we know from external reports that they raised $75M, the deck itself is silent on the financial requirements.

2. Clinical Data: While the deck mentions 'groundbreaking scientific discoveries,' it lacks specific data plots (e.g., mouse model tumor shrinkage or T-cell activation assays) in this summary version. Investors in a $75M round would typically see a much larger technical appendix with raw data.

3. Intellectual Property Detail: Although the CEO’s 110+ patents are mentioned, a specific slide detailing the patent estate (filing dates, jurisdictions, and coverage for lead assets GIM-122/531/407) is absent.

Founder's Guide: What to Copy

1. The Pipeline Graphic: Copy the layout of Slide 5. It clearly distinguishes between 'Clinical Programs,' 'Drug Candidates,' and 'Development Programs,' giving the impression of a mature, multi-asset company even at the Series A stage.

2. The 'Homeostasis' Framework: If your technology can be applied to multiple industries or disease states, use a 'balance' or 'spectrum' visual like Slide 3 to show how one platform solves two different problems.

3. The Partnership Slide: If you have a partnership with a major player (like Verily), don't just put their logo on a 'Partners' slide. Dedicate a full slide (like Slide 11) to explaining exactly how that partnership accelerates your development or reduces your risk.